Previous 10 | Next 10 |
BioStem provides a business update and highlights recent accomplishments Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million National Pricing for Amniowrap2™ effective January 1 st in all 50 states and territories POMP...
POMPANO BEACH, Fla., Jan. 11, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc . (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed a ...
POMPANO BEACH, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc . (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed Mr...
POMPANO BEACH, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced that the Center for Medicare Servi...
POMPANO BEACH, Fla., Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc . (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces the appointment of M...
2023-11-14 10:58:43 ET BioStem Technologies press release ( OTCPK:BSEM ): Q3 GAAP EPS of $0.03. Revenue of $3.6M (+227.3% Y/Y). For further details see: BioStem Technologies GAAP EPS of $0.03, revenue of $3.6M
POMPANO BEACH, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the quarter ended September 30,...
POMPANO BEACH, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc . (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today announced that the Centers for ...
POMPANO BEACH, FL / ACCESSWIRE / November 6, 2023 / BioStem Technologies Inc. (OTC PINK:BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release i...
POMPANO BEACH, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announces that it has closed an oversu...
News, Short Squeeze, Breakout and More Instantly...
BioStem Technologies Inc Company Name:
BSEM Stock Symbol:
OTCMKTS Market:
BioStem Technologies Inc Website:
POMPANO BEACH, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that an article validating ...
Please note: this Update is being issued for ticker indexing purposes. The content of the release itself remains the same. NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive interview with Jason Matuszewski, CEO of BioStem Technologies, Inc. ( OTC: BSE...
POMPANO BEACH, Fla., May 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics, will sponsor the MRO Better Half Dash which will be held on May 29, 2...